← Eli Lilly and overview

Eli Lilly and vs Roche: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Eli Lilly and Company (LLY)

Q3 2026
▲2▼2

Lilly hits $1T on obesity demand, but competition and coverage risks rise

  • Obesity drug demand drives record revenue and $1T valuation Revenue jumped 47.7% to $22.97 billion, with Mounjaro sales up 91%, pushing Lilly past a $1 trillion market value. The company raised its financial guidance, showing the obesity-drug boom is still accelerating.

    This is the core positive force behind Lilly's price surge in Q3.

  • Pipeline and access expand Lilly acquired AtaiBeckley, reported positive Alzheimer's data, won cancer and insulin approvals, and expanded access to its oral GLP-1 Foundayo through Amazon and CVS. A new $6.5 billion Houston plant will boost supply.

    These moves broaden Lilly's product lineup and make its drugs easier to get, supporting future growth.

  • Competition intensifies as Novo Nordisk scores wins Novo Nordisk won EU approval for oral Wegovy, and its CagriSema beat Zepbound in a head-to-head trial (12.4% vs. 9.1% weight loss). This threatens Lilly's dominance in the obesity market.

    Rising competition is a key risk that could pressure Lilly's market share and pricing.

  • Regulatory and coverage headwinds mount Retatrutide's FDA filing slipped to 2027 due to a heart-event imbalance, Germany's rebate reform led to manufacturing cuts, and about 14% of US employers plan to drop GLP-1 coverage by 2027.

    These setbacks could delay a key drug and reduce future sales, weighing on investor sentiment.

September 2026
▲3▼1

Lilly hits $1T on obesity drug strength, but Novo's rival shows better weight loss

  • Lilly crosses $1 trillion market value Eli Lilly became a $1 trillion company, powered by its obesity drugs. Mounjaro sales jumped 91% and overall quarterly revenue rose 47.7%, showing the huge demand for its weight-loss and diabetes treatments.

    This milestone reflects the core driver of Lilly's valuation and investor enthusiasm during the period.

  • New oral pill Foundayo gains traction Lilly launched its oral GLP-1 pill Foundayo in the UK, and it captured about a third of new US oral GLP-1 patients. This expands Lilly's reach beyond injections and taps into patient preference for pills.

    Foundayo's uptake is a new product-level success that broadens Lilly's obesity franchise.

  • Pipeline and manufacturing advances Lilly won FDA approvals for a breast cancer combo and weekly insulin Onswik, closed the AtaiBeckley deal, and broke ground on a $6.5 billion Houston plant. These moves strengthen its long-term growth and supply capacity.

    These are concrete new developments that support future revenue and production scale.

  • Novo's CagriSema beats Zepbound in trial Novo Nordisk's CagriSema helped patients lose 12.4% weight versus 9.1% for Lilly's Zepbound/tirzepatide in a head-to-head trial. If approved, this could slow Lilly's market-share gains in obesity.

    This competitive threat is a key counterweight to Lilly's positive momentum.

Latest
▲3▼1

Lilly's pipeline wins and Foundayo growth offset Novo's competitive threat

  • Foundayo captures one-third of new oral GLP-1 patients Lilly's oral weight-loss pill Foundayo now accounts for about one-third of new patients starting oral GLP-1 medicines, with market share rising weekly. This shows real commercial traction, supporting future sales growth and reinforcing Lilly's obesity franchise.

    Demonstrates Foundayo's rapid adoption, a key growth driver for Lilly's obesity business.

  • Retatrutide delivers up to 20.8% weight loss in Phase 3 Lilly's next-generation obesity drug retatrutide helped patients lose up to 20.8% of body weight in a Phase 3 trial, with many no longer meeting obesity criteria. This strengthens Lilly's pipeline and future growth prospects beyond current drugs.

    Positive clinical data for a key pipeline asset boosts long-term revenue potential.

  • Foundayo cuts cardiovascular risk in large trial Foundayo reduced heart risks by 16% versus insulin in a major trial, with lower death rates. This could expand its use to heart patients, boosting sales and differentiating it from competitors.

    Cardiovascular benefit expands Foundayo's label potential and market reach.

  • Novo's CagriSema beats Lilly's tirzepatide in head-to-head Novo Nordisk's CagriSema helped patients lose 12.4% weight versus 9.1% for Lilly's tirzepatide in a Phase 3 trial. This competitive threat could slow Lilly's market share gains if CagriSema wins approval.

    Direct competitive loss in a key trial poses a risk to Lilly's obesity leadership.

▲3▼1

Lilly's pipeline and manufacturing expand as competition intensifies

  • FDA approves new breast cancer combo The FDA granted full approval to Lilly's Inluriyo plus Verzenio for ESR1-mutated breast cancer, based on a trial where the combo doubled progression-free survival versus Inluriyo alone. This expands Lilly's oncology offerings and adds a new revenue stream, helping diversify beyond obesity drugs.

    New approval directly boosts Lilly's oncology business and revenue potential.

  • Lilly breaks ground on $6.5B Houston plant Lilly started building a $6.5 billion manufacturing site in Houston to produce active ingredients for its medicines, including the oral obesity drug Foundayo. This is part of a $50 billion U.S. investment to expand capacity and secure supply for future growth.

    Major capital investment supports long-term production capacity and supply chain.

  • Novo's CagriSema beats Zepbound in head-to-head trial In a phase 3 trial, Novo's CagriSema helped patients lose 12.4% of their weight over 60 weeks, compared to 9.1% for Lilly's Zepbound. This suggests a competitive threat in the obesity market, potentially slowing Lilly's market share gains if CagriSema wins approval.

    Direct competitive trial result could pressure Lilly's obesity franchise.

  • FDA approves once-weekly insulin Onswik The FDA approved Lilly's Onswik, a once-weekly basal insulin for type 2 diabetes, which cuts injections from daily to weekly. This strengthens Lilly's diabetes portfolio and offers a more convenient option, potentially capturing market share from daily insulins.

    New product approval expands diabetes franchise and addresses patient convenience.

▲4

Lilly's obesity lead widens as pipeline deals and analyst targets climb

  • Foundayo grabs 30% of new US oral weight-loss patients Lilly's new obesity pill Foundayo has captured over 30% of new US patients starting oral weight-loss medicines, up from almost nothing. Novo's Wegovy pill once held about 90% of that market. This shows Lilly is winning real prescriptions, not just headlines, which supports future sales.

    Concrete evidence that Lilly's newest product is taking market share, a key growth driver.

  • Citi raises Lilly target to Street-high $1,600 Citi lifted its Lilly price target to $1,600, implying about 45% upside, even after the stock fell 8% in a month. The analyst points to Lilly's dominance in obesity prescriptions, Foundayo's prescriber growth, and retatrutide's strong trial results. This boosts investor confidence.

    A major analyst upgrade directly addresses why the stock could move higher despite recent weakness.

  • Lilly completes AtaiBeckley deal for depression drug Lilly closed its acquisition of AtaiBeckley, adding BPL-003, a rapid-acting treatment for depression that resists standard therapy. This expands Lilly's neuroscience pipeline beyond obesity, using its cash to plant seeds for future growth. It reduces reliance on weight-loss drugs.

    Shows Lilly is actively diversifying into new treatment areas, a strategic positive.

  • New data and deals bolster pipeline at EASD and beyond Lilly will present strong trial data for retatrutide, Foundayo, and eloraTZP at a major diabetes conference. It also signed new research deals with QurCan and Twist Bioscience. These moves strengthen Lilly's pipeline and technology, supporting long-term growth even if they don't boost sales immediately.

    Highlights ongoing pipeline progress and partnerships that underpin future revenue.

▲4

Lilly hits $1 trillion as obesity drugs and pipeline deals drive growth

  • Lilly hits $1 trillion market cap on obesity drug strength Lilly crossed $1 trillion in market value, with Q2 revenue up 47.7% and Mounjaro sales up 91%. The obesity franchise and expanded access are powering growth, and analysts see more upside.

    This milestone reflects the scale of Lilly's success and investor confidence, directly answering why the stock is moving.

  • J.P. Morgan raises estimates on obesity drug growth J.P. Morgan lifted 2027 revenue and EPS forecasts, keeping an Overweight rating and $1,400 target. It expects incretin sales to exceed $100 billion by 2030, driven by Zepbound, Mounjaro, and Foundayo.

    Analyst upgrades signal growing confidence in Lilly's long-term growth, a key driver of stock movement.

  • Lilly launches Foundayo in UK, first European market Lilly launched its oral weight-loss pill Foundayo in the UK, the first European market. The pill costs £100-£120 per month, much less than injections, potentially widening access and boosting sales.

    This is a concrete step in expanding Lilly's obesity franchise globally, directly supporting future revenue growth.

  • Lilly builds neuroscience as new growth driver Neuroscience revenue grew 32% to $811 million in H1 2026, led by Kisunla. Acquisitions like AtaiBeckley and Centessa add pipeline assets, diversifying beyond obesity and reducing reliance on GLP-1 drugs.

    This shows Lilly's efforts to create a second growth engine, which could sustain long-term growth and attract investors.

August 2026
▲3▼1

Lilly's Q2 Beat, Pipeline Wins Offset Rising Competition and Coverage Risks

  • Q2 earnings beat and guidance raise Lilly's Q2 revenue jumped 47.7% to $22.97 billion, beating expectations, with Mounjaro and Zepbound making up 65% of sales. Management raised guidance, signaling confidence in continued momentum.

    This is the core new financial result that drove the stock in August.

  • Pipeline and access expansion Lilly widened its lead over Novo Nordisk after CagriSema disappointed. Foundayo won UK approval, cheap access expanded via Amazon and CVS, and new deals in Alzheimer's, oncology, RNA vaccines, and immunology strengthened the pipeline.

    These new developments support future growth and competitive positioning.

  • Label expansions and cost savings Mounjaro gained a heart-risk label, broadening its use, and Zepbound showed cost savings, reinforcing its value proposition. These updates could boost demand and payer acceptance.

    New label and cost data are incremental positives for the franchise.

  • Competition and coverage headwinds Novo Nordisk launched oral Wegovy in Germany and expects a fragmented obesity market. About 14% of US employers plan to drop GLP-1 coverage by 2027, which could slow US sales growth.

    These are new competitive and reimbursement risks that could pressure future sales.

▲3▼1

Lilly's heart-label win and pipeline deals widen its lead

  • FDA expands Mounjaro label to cut heart risks The FDA approved Mounjaro to lower the risk of heart attacks, strokes and heart-related death in high-risk type 2 diabetes patients. This makes the drug useful for more people, supporting sales and pricing power, though it also increases pressure on manufacturing capacity and insurance coverage.

    A new regulatory approval directly expands the market for Lilly's biggest drug.

  • Taltz plus Zepbound shows durable one-year benefit Phase 3b trials showed combining Taltz and Zepbound helped patients with psoriatic disease and obesity achieve clearer skin and more weight loss than Taltz alone after a year. This supports using Lilly drugs together, which could boost sales across both products.

    New clinical data supports broader use of two Lilly drugs together.

  • Lilly buys Merida Biosciences for up to $2.875 billion Lilly agreed to buy Merida Biosciences for up to $2.875 billion, gaining an early-stage immunology drug for Graves' disease and thyroid eye disease. This uses cash from Lilly's obesity franchise to diversify into new treatment areas, though the drug is still years from market.

    A major acquisition shows Lilly using its cash to build new growth beyond weight-loss drugs.

  • Novo launches oral Wegovy in Germany as competition builds Novo Nordisk launched its Wegovy pill in Germany, the EU's largest drug market, and expects pills to take over a third of GLP-1 use by 2030. Lilly's Foundayo pill is in Britain and targeting 40+ markets, so this is a real race for the oral obesity market.

    A direct competitor's launch in a key market threatens Lilly's share of the growing oral GLP-1 market.

▲3▼1

Lilly's GLP-1 lead widens, but employer coverage and pricing risks build

  • Zepbound shown to cut healthcare costs in older adults A real-world study found Zepbound users over 55 had up to 38% lower healthcare costs, with savings reaching $607 per patient per month by 12 months. This evidence could persuade Medicare and insurers to cover obesity drugs, supporting demand.

    This new study directly addresses payer resistance, a key risk, by showing cost savings that could expand coverage and demand.

  • 14% of US employers to drop obesity drug coverage by 2027 A survey shows about 14% of US employers plan to end GLP-1 coverage by 2027 due to rising costs, with the share covering obesity drugs already falling from 72% to 60%. This could reduce Zepbound prescriptions and slow US sales growth.

    This is a new, concrete threat to demand from a major payer group, directly countering the positive coverage narrative.

  • FDA clears Lilly-Roche Alzheimer's blood test The FDA cleared the Elecsys pTau217 blood test, developed with Roche, as the first single-biomarker test to rule in or out Alzheimer's amyloid pathology. This could expand diagnosis and boost the market for Lilly's Alzheimer's drug donanemab.

    This new approval opens a path to wider Alzheimer's diagnosis and treatment, a potential new growth area beyond GLP-1 drugs.

  • Oncology portfolio grows 11%, diversifying beyond GLP-1 Lilly's oncology revenue rose 11% to $4.84 billion in the first half, with newer drugs like Jaypirca up 66% and Inluriyo contributing $110 million. This shows Lilly is building a second growth engine, reducing reliance on obesity drugs.

    This new data highlights a broadening revenue base, which is important for long-term growth and risk reduction.

▲3▼1

Lilly's obesity franchise keeps winning as pipeline and global reach expand

  • UK approves Foundayo for weight loss and diabetes Britain cleared Lilly's once-daily weight-loss pill Foundayo for both obesity and type 2 diabetes, the first European approval. A pill is easier for patients than injections, so it opens a new market and widens Lilly's lead over Novo's rival pill.

    New regulatory approval expands Lilly's addressable market and competitive position.

  • Lilly adds Alzheimer's and ion channel deals Lilly bought rights to an early-stage Alzheimer's drug for $10 million upfront (up to $1 billion more if it works) and teamed up with OmniAb on an ion channel program worth up to $370 million. These small bets refill the pipeline beyond weight-loss drugs.

    New deals diversify Lilly's pipeline and reduce reliance on GLP-1s.

  • Lilly partners on RNA vaccines Lilly signed a research and licensing deal with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseases, with options for two more targets. It is an early-stage move into a new treatment area, using Lilly's cash to plant seeds for future growth.

    New collaboration expands Lilly's technology base into vaccines.

  • Novo CEO says obesity market won't be winner-take-all Novo Nordisk's chief said the obesity market will split among many players, like different soda brands, rather than one winner. Novo's oral Wegovy already holds 90% of the oral GLP-1 market. This is a reminder that Lilly's dominance may face limits as competition grows.

    A real counterweight: competition could cap Lilly's long-term market share.

▲4

Lilly's obesity franchise keeps winning as new markets and legal wins add up

  • UK approves Foundayo, first market outside US Britain's regulator cleared Lilly's once-daily weight-loss pill Foundayo, the first approval outside the US. This opens a new market for a pill version of its obesity drug, which could reach patients who dislike injections. It is not yet sold through the NHS while cost regulators review it.

    A brand-new regulatory approval expands Lilly's addressable market beyond the US.

  • Amazon and CVS widen cheap access to Lilly drugs Amazon Pharmacy will offer Lilly's Zepbound pen and Foundayo pill to Medicare patients for $50 a month, and CVS expanded its weight-management program with Lilly, adding app-based access and $29 clinic visits. Easier, cheaper access should lift prescription volumes.

    New distribution deals directly increase how many patients can get Lilly's drugs.

  • Lilly sues sellers of unapproved retatrutide Lilly filed six lawsuits against businesses selling unapproved versions of retatrutide, its experimental obesity drug, and has referred over 200 parties to authorities. This protects the future franchise from unsafe copycats and keeps the market ready for the real drug when approved.

    Legal action defends a key future growth driver from illicit competition.

  • Analysts raise targets on international obesity opportunity BofA lifted its Lilly price target to $1,344 and said overseas obesity sales could eventually beat the US, with most Foundayo peak sales expected abroad. Other banks also raised targets after strong Q2 results. This reflects growing confidence in Lilly's global growth runway.

    Analyst upgrades signal that the market sees more upside from international expansion.

▲4

Lilly's Q2 Beat and Raised Guidance Cement Obesity-Drug Dominance

  • Q2 beat and raised guidance Lilly reported Q2 revenue of $22.97 billion, up 47.7%, and adjusted EPS of $8.38, beating estimates by 27%. Management raised full-year revenue guidance to $85–$87 billion and EPS to $36.25. The stock jumped as much as 7% on the news, reflecting strong demand for its obesity and diabetes drugs.

    This is the core new event that directly answers why LLY is moving right now.

  • Mounjaro and Zepbound sales surge Mounjaro sales jumped 91% to $9.94 billion and Zepbound brought in $4.93 billion, together 65% of total revenue. This shows Lilly's GLP-1 franchise is still growing rapidly, driving the earnings beat and giving confidence that demand remains strong despite competition.

    It explains the fundamental driver behind the beat-and-raise and the stock's move.

  • Novo Nordisk's setback boosts Lilly's competitive edge Novo Nordisk's next-generation obesity drug CagriSema fell short of Lilly's Zepbound in blood sugar control, and Novo guided to a sales decline and cut 9,000 jobs. This strengthens Lilly's position as the clear leader in the obesity market, which supports its pricing power and long-term growth.

    It highlights a key competitive shift that benefits Lilly and is new information.

  • Retatrutide filing planned for early 2027 Lilly plans to file for approval of its next-generation obesity drug retatrutide in early 2027. The drug helped patients lose over 20% of body weight and could also treat sleep apnea and reduce heart risk. Analysts see it as a future growth driver, though it won't contribute revenue until after 2027.

    It is a new pipeline update that reinforces Lilly's long-term growth story.

July 2026
▲2▼1

Lilly hits record on obesity demand, but competition and delays loom

  • Obesity drug demand drives record results Lilly hit record highs as demand for its obesity drugs surged, with revenue jumping 55.5% to $19.8 billion and guidance raised. JPMorgan lifted its price target to $1,400, reflecting strong confidence.

    This is the core positive driver of the stock's record performance in July.

  • Pipeline expansion and strategic investments Lilly expanded its pipeline through the $3.8 billion AtaiBeckley acquisition, positive Alzheimer's data, Canadian approval for Ebglyss, U.S. manufacturing investment, and an AI drug-discovery alliance, supporting future growth.

    These moves strengthen Lilly's long-term growth prospects and diversify its business.

  • Retatrutide shows promise but faces delays Retatrutide showed strong Phase 3 weight loss, but a heart-event imbalance bears watching. Its FDA filing slipped to early 2027 due to manufacturing data gaps, delaying a key growth driver.

    This is a key pipeline update with both positive efficacy and negative regulatory delay.

  • Competition and policy headwinds intensify Germany's rebate reform prompted Lilly to scale back manufacturing there, and Novo Nordisk won EU approval for oral Wegovy, intensifying competition. These pressures could weigh on future sales and margins.

    These are significant risks that emerged in July and could impact Lilly's growth trajectory.

▲4

Lilly's GLP-1 dominance grows as pipeline and supply expand

  • Q1 revenue surges 55.5% on Foundayo launch Lilly's first-quarter revenue jumped 55.5% to $19.8 billion, beating estimates, as new oral GLP-1 Foundayo and strong Mounjaro and Zepbound sales drove growth. Management raised full-year guidance, and an analyst set a $1,365 price target, reinforcing confidence in Lilly's earnings power.

    This shows the core financial engine behind Lilly's stock and why analysts remain bullish.

  • Retatrutide Phase 3 success, FDA filing planned Lilly's next-generation obesity drug retatrutide cut weight by up to 22.6% in Phase 3 trials, with a planned FDA submission in early 2027. This strengthens Lilly's future obesity franchise, though a slight imbalance in serious heart events bears watching.

    It confirms a major future growth driver and addresses the earlier delay, showing the pipeline is back on track.

  • Lilly expands US manufacturing with Resilience Lilly and Resilience are investing $750 million to expand U.S. production of the KwikPen injectable device, creating 400 jobs and boosting supply capacity for diabetes and obesity medicines. This helps ensure Lilly can meet soaring demand and reduces reliance on foreign manufacturing.

    It directly addresses supply constraints that could limit growth and shows Lilly investing in its core business.

  • Lilly joins Illumina's AI drug discovery alliance Lilly became a foundational participant in Illumina's Billion Cell Atlas, gaining access to massive genetic data to speed AI-driven drug discovery. This long-term move could help diversify Lilly's pipeline beyond GLP-1 drugs and keep it at the forefront of biotech innovation.

    It signals a strategic push into next-generation technology that could yield new drugs and reduce reliance on one franchise.

▲1▼1

Lilly buys depression pipeline, but retatrutide filing slips to 2027

  • Lilly to buy AtaiBeckley for up to $3.8B Lilly agreed to pay $2.8 billion upfront, plus up to $1 billion more if milestones are met, for AtaiBeckley and its experimental psychedelic depression treatment. It uses Lilly's cash to add a new growth area beyond weight-loss drugs, though the upfront cost is real.

    This is the period's biggest new deal and shows how Lilly is spending its obesity-drug profits to diversify.

  • Retatrutide approval filing delayed to early 2027 Lilly pushed back its filing for next-generation obesity drug retatrutide because it needs more manufacturing and quality-control data for regulators. The drug still worked well in trials, but the delay means a key future growth driver arrives later than expected.

    This is the main new negative and directly affects Lilly's next big obesity-drug opportunity.

▼2▲1

Lilly's obesity franchise powers growth as it expands into new drug areas

  • Germany's cost reform raises rebates, Lilly to scale back manufacturing Germany passed a law forcing drugmakers to pay higher rebates, aiming to cut €16 billion in health costs. Lilly's CEO said the company will scale back manufacturing plans there, a real headwind for its European business and investment.

    A concrete regulatory setback that could hurt Lilly's sales and expansion in a major market.

  • Lilly acquires AtaiBeckley for up to $3.8 billion Lilly is buying psychedelic drugmaker AtaiBeckley for about $2.8 billion upfront plus up to $1 billion in milestones. This adds a promising treatment for resistant depression to Lilly's pipeline, showing it is using its cash to expand beyond weight-loss drugs.

    A new strategic move that broadens Lilly's pipeline and signals long-term growth ambitions.

  • Novo Nordisk wins EU approval for oral Wegovy Novo Nordisk got EU clearance for the first oral GLP-1 pill for weight management, giving patients a pill option alongside injections. This intensifies competition for Lilly's obesity drugs in Europe, where pill preference could shift market share.

    A direct competitive threat in the key obesity market that could pressure Lilly's growth.

▲3

Lilly rides obesity-drug demand and Medicare expansion to record highs

  • JPMorgan raises price target to $1,400, stock hits record JPMorgan lifted its LLY target from $1,300 to $1,400 and reiterated overweight, citing strong demand for Mounjaro and Zepbound. The stock hit an all-time high above $1,200, with market cap surpassing $1.1 trillion. Analyst expects Q2 earnings to beat consensus.

    This is a new analyst action that directly boosted the stock and reflects confidence in future growth.

  • Lilly presents Alzheimer's data at AAIC 2026 Lilly will present 16 abstracts at the Alzheimer's conference, including new data on its Kisunla treatment and a P-tau217 blood test that could simplify diagnosis. This advances its pipeline beyond obesity, offering another long-term growth driver.

    This is a new pipeline update that shows Lilly's broader research strength beyond weight-loss drugs.

  • Canada backs Lilly's eczema drug Ebglyss Canada's drug agency gave a positive recommendation for Lilly's eczema treatment Ebglyss, which could lead to public reimbursement and wider patient access. Ebglyss is already approved in Canada and other countries, and this expands its reach.

    This is a new regulatory win that broadens Lilly's revenue base beyond obesity and diabetes.

Q2 2026
▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

June 2026
▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

Roche Holding AG (ROP.SW)

Q3 2026
▲2▼2

Roche Q3: Pipeline Wins, Alzheimer's Progress, But Profit Hit by Franc and Trial Halts

  • Alzheimer's blood test and strong data Roche reported strong Alzheimer's data and received FDA clearance for an Alzheimer's blood test, plus expanded HER2 testing. These advances could open new revenue streams in diagnostics and treatment.

    New positive developments in Alzheimer's and diagnostics that could drive future growth.

  • Nurix deal and Phase III wins A $2.3bn Nurix deal and multiple Phase III wins, including Vabysmo's durable eye data, strengthened Roche's pipeline. Better-than-expected H1 earnings and reaffirmed guidance boosted confidence.

    New partnership and clinical successes that reinforce growth prospects.

  • Profit drop and trial halts H1 net profit fell 6–7% due to a strong Swiss franc, and two Huntington's studies plus a partnered BioNTech cancer vaccine trial were halted. These setbacks weighed on sentiment.

    New negative events that directly impacted financials and pipeline confidence.

  • Tariffs and competitive pressures US tariffs on EU drugs threatened margins, while competition, Medicare pricing, China pressures, and obesity-market execution remained concerns. Lilly and Novo's leadership added to the challenges.

    Ongoing external and competitive risks that could limit upside.

September 2026
▲2▼1

Roche's pipeline surges with FDA wins and Phase III successes

  • Multiple Phase III wins and regulatory advances Roche reported Phase III successes in lung cancer (Tam-Peli), follicular lymphoma (Lunsumio), IgA nephropathy (sefaxersen), and obesity/diabetes (enicepatide), plus Priority Review for Enspryng in MOGAD and European label expansions for Ocrevus and Susvimo.

    These pipeline wins broaden Roche's treatment portfolio and support future revenue growth.

  • New discovery partnerships Roche formed new discovery partnerships with Dualitas, Atavistik, and Earendil, investing in early-stage science to replenish its pipeline and access external innovation.

    These deals show Roche's commitment to long-term growth through external innovation.

  • Competitive and pricing pressures persist Novartis competition in MS, US Medicare pricing discouraging a breast-cancer launch, and the discontinued obesity drug emugrobart weigh on Roche. China and obesity pricing/execution pressure, plus Lilly/Novo leadership, remain material risks.

    These counterweights highlight ongoing challenges that could limit Roche's growth.

Latest
▲3▼1

Roche's pipeline wins and new deals outweigh one obesity setback

  • Roche adds two new drug-discovery partnerships Roche signed collaborations with Dualitas (bispecific antibodies, up to $1 billion) and Atavistik Bio (allosteric medicines, up to $1.9 billion), plus an AI cancer-antibody deal with Earendil Labs. These add future pipeline assets at modest upfront cost, supporting long-term growth expectations.

    New licensing deals expand Roche's pipeline and are a core driver of future revenue.

  • European approvals widen Ocrevus and Susvimo labels CHMP backed Ocrevus for children and teens with relapsing MS, and the European Commission approved Susvimo for a common cause of vision loss in older people. Both expand the patient pool for existing drugs, adding revenue in Europe.

    New regulatory approvals directly expand market access and sales for Roche medicines.

  • Fenebrutinib and giredestrant advance toward US approval The FDA accepted Roche's fenebrutinib application for two forms of MS under priority review, and accepted giredestrant filings in breast cancer after Phase III data showed a 44% cut in progression risk. Both could become significant new products.

    Late-stage regulatory filings are key milestones that can convert pipeline promise into revenue.

  • Roche halts obesity drug emugrobart; competition and pricing pressure persist Roche discontinued emugrobart (GYM329) for obesity, returning rights to Chugai, which hit a year-to-date low. Analysts also flag execution and pricing pressure in China and obesity, where Eli Lilly and Novo Nordisk lead. This is a real counterweight to the pipeline wins.

    A pipeline failure and competitive pressure are the main negatives weighing on Roche's outlook.

▲4▼1

Roche's pipeline wins offset US pricing risk

  • Lung cancer drug Tam-Peli wins Phase III Roche's licensed Tam-Peli cut death risk by 54% in relapsed small-cell lung cancer, with strong survival and response gains. Roche holds worldwide rights outside China, so this supports a future growth driver and lifts confidence in its pipeline.

    A major late-stage win that adds a new potential cancer treatment to Roche's pipeline.

  • Lunsumio combo succeeds in follicular lymphoma Lunsumio plus Revlimid met its Phase III goal in follicular lymphoma, improving progression-free survival versus standard care. This supports full approval and a broader use, strengthening Roche's blood-cancer franchise and future sales.

    A confirmatory trial win that could expand an approved drug's label and revenue.

  • Obesity drug enicepatide hits Phase II goals Roche's once-weekly enicepatide met both goals in a mid-stage trial, cutting blood sugar and weight strongly. This advances its obesity/diabetes pipeline into Phase III, opening a large new market despite rising competition.

    A key pipeline asset showing strong results in a huge potential market.

  • Kidney disease drug sefaxersen succeeds Genentech's sefaxersen met its Phase III goal in IgA nephropathy, sharply reducing protein in urine with best-in-class potential. This adds a promising kidney-disease treatment to Roche's late-stage pipeline, supporting future growth.

    Another late-stage pipeline win that broadens Roche's potential treatment portfolio.

  • US Medicare pricing pressure may delay launches Roche said it may not launch a new oral breast cancer drug, citing US Medicare price alignment that cuts incentives. This regulatory risk could reduce future revenue from new medicines and shows how US pricing policy weighs on Roche's plans.

    A concrete regulatory threat that could limit Roche's ability to launch and profit from new drugs.

▲3▼1

Roche's Diagnostics and Drug Pipeline Advance, Offsetting Competition

  • Alzheimer's Blood Test FDA Clearance FDA cleared Roche and Lilly's Elecsys pTau217 blood test for Alzheimer's, available on Roche's 4,500 US lab machines. This opens a large new testing market and strengthens Roche's diagnostics leadership, supporting future revenue growth.

    This is a new regulatory win that expands Roche's diagnostics franchise and addresses a major unmet need.

  • Enspryng Priority Review for MOGAD FDA granted Priority Review to Roche's Enspryng for MOGAD, a rare autoimmune disease with no approved treatments. If approved, it would be first-in-class, adding a new growth driver and reinforcing Roche's neuroscience portfolio.

    This is a new regulatory milestone that could lead to a first-in-class therapy and new sales.

  • Blood-Cancer Deal with Simcere Roche committed $75 million upfront for global rights to Simcere's experimental blood-cancer drug SIM0660, in a deal worth up to $1.53 billion. The low upfront cost limits risk while adding a potential future pipeline asset.

    This is a new business development move that expands Roche's oncology pipeline with limited near-term financial risk.

  • Novartis Competition in MS Novartis's remibrutinib showed positive Phase 3 results in multiple sclerosis, with analysts estimating $3 billion in peak sales. This could challenge Roche's BTK inhibitor in MS, creating competitive pressure on future sales.

    This is a new competitive threat that could limit Roche's market share in multiple sclerosis.

August 2026
▲3▼1

Roche's diagnostics win big; cancer vaccine setback offsets

  • Alzheimer's blood test cleared by FDA Roche won FDA clearance for the first blood test that helps diagnose Alzheimer's amyloid buildup, usable on its 4,500 US lab machines. This opens a large new testing market and strengthens Roche's diagnostics leadership, a clear positive for future revenue.

    It is the period's biggest new approval and a first-of-its-kind product, directly lifting Roche's growth outlook.

  • HER2 cancer tests approved for wider use FDA expanded approval of Roche's HER2 companion tests to guide treatment in gastroesophageal cancer, a hard-to-treat disease with no prior approved test. This widens the patient pool for Roche's diagnostics and supports its personalized-medicine franchise.

    A new regulatory win that broadens Roche's diagnostic portfolio and adds revenue potential.

  • Vabysmo shows strong two-year eye data Roche's Vabysmo kept improving vision and retinal health in a severe eye disease over two years, with most patients needing treatment only every 20 weeks. Longer dosing intervals make the drug more attractive versus rivals, supporting sales growth.

    New clinical data strengthens the case for a key Roche drug and its competitive position.

  • Partnered cancer vaccine trial halted BioNTech stopped a mid-stage trial of an mRNA cancer vaccine developed with Roche after a safety board saw worse survival in one arm. This removes a hoped-for pipeline win and dents confidence in Roche's cancer vaccine bet.

    It is the period's main negative, a real counterweight to the diagnostic wins.

▲3▼1

Roche's diagnostics win big; cancer vaccine setback offsets

  • Alzheimer's blood test cleared by FDA Roche won FDA clearance for the first blood test that helps diagnose Alzheimer's amyloid buildup, usable on its 4,500 US lab machines. This opens a large new testing market and strengthens Roche's diagnostics leadership, a clear positive for future revenue.

    It is the period's biggest new approval and a first-of-its-kind product, directly lifting Roche's growth outlook.

  • HER2 cancer tests approved for wider use FDA expanded approval of Roche's HER2 companion tests to guide treatment in gastroesophageal cancer, a hard-to-treat disease with no prior approved test. This widens the patient pool for Roche's diagnostics and supports its personalized-medicine franchise.

    A new regulatory win that broadens Roche's diagnostic portfolio and adds revenue potential.

  • Vabysmo shows strong two-year eye data Roche's Vabysmo kept improving vision and retinal health in a severe eye disease over two years, with most patients needing treatment only every 20 weeks. Longer dosing intervals make the drug more attractive versus rivals, supporting sales growth.

    New clinical data strengthens the case for a key Roche drug and its competitive position.

  • Partnered cancer vaccine trial halted BioNTech stopped a mid-stage trial of an mRNA cancer vaccine developed with Roche after a safety board saw worse survival in one arm. This removes a hoped-for pipeline win and dents confidence in Roche's cancer vaccine bet.

    It is the period's main negative, a real counterweight to the diagnostic wins.

July 2026
▲3▼1

Roche gains on pipeline wins and earnings despite profit dip and tariffs

  • Pipeline and diagnostic advances Roche reported positive Alzheimer's data, progress on a blood test, a new TB test, a lupus submission, FDA priority review for Gazyva, and EU backing for Susvimo. These advances support future sales growth.

    These pipeline and diagnostic wins were key positive drivers during the period.

  • Nurix deal and analyst support Roche agreed to a $2.3bn deal with Nurix for blood-cancer drugs, and UBS favored Roche over AI. The deal expands the pipeline, while analyst backing boosted investor confidence.

    The Nurix acquisition and UBS preference were notable positive developments.

  • Earnings beat and reaffirmed guidance Shares jumped 5% after Roche reaffirmed guidance and reported better-than-expected H1 earnings, helped by a lower generic-loss forecast. This reassured investors about the company's outlook.

    The earnings beat and guidance reaffirmation directly lifted the stock.

  • Profit dip, study halts, competition, tariffs H1 net profit fell 6–7% on the strong franc; two Huntington's studies were discontinued; Outlook Therapeutics' Lytenava approval adds eye-disease competition; and new US tariffs on EU drugs threaten exports and margins.

    These setbacks weighed on sentiment and pose risks to future performance.

▲3▼1

Roche gains on outlook, drug wins, but tariffs and competition weigh

  • Roche reiterates 2026 outlook, shares jump 5% Roche reaffirmed its full-year guidance, reassuring investors and sending shares up about 5%. This signals confidence in future earnings and reduces uncertainty, supporting the stock price.

    This is the biggest single-day move and directly answers why the stock moved.

  • New US tariffs on EU drugs threaten Roche's exports Trump announced phased tariffs on generic drug imports, with rates up to 200% by 2029, and new 10-12.5% tariffs on EU goods including pharmaceuticals. As a major EU drug exporter, Roche faces higher costs and potential sales pressure, a negative for the stock.

    This is a new, material risk that could hurt Roche's US sales and profitability.

  • Roche wins FDA clearance for diagnostic and EU backing for eye implant Roche received FDA clearance for its cobas BV/CV assay and EU recommendation for Susvimo eye implant. These expand its diagnostics and treatment offerings, adding future revenue streams and strengthening its pipeline.

    New approvals directly support future sales growth and pipeline strength.

  • Nurix and Labcorp advances boost Roche's pipeline and diagnostics Nurix enrolled the first patient in a Phase 3 trial of bexobrutideg with Roche, and Labcorp launched Roche's PTEN companion diagnostic nationwide. These advances validate Roche's collaboration strategy and expand its diagnostic reach, supporting long-term growth.

    These are new positive developments that show pipeline and diagnostic progress.

▲2▼1

Roche's H1 profit falls on franc, but pipeline and diagnostics advance

  • Strong Swiss franc cuts reported H1 profit Roche's first-half net profit fell 6-7% to about 6.9-7.3 billion francs, mainly because the strong Swiss franc reduced the value of overseas sales. This headline weakness can pressure the stock, even though sales rose 6% in constant currency.

    This is the main negative force this period, explaining why reported earnings look weak.

  • Lower generic hit and better-than-expected earnings lift shares Roche cut its expected 2026 generic sales loss to about 600 million francs from 1 billion, and first-half earnings beat expectations. Shares jumped 3.2% as investors saw less near-term revenue erosion, though full-year guidance was unchanged.

    This is the key positive surprise that drove the stock up on results day.

  • New drug and diagnostic approvals expand future sales Roche won FDA priority review for Gazyva in a kidney disease, CHMP backing for Susvimo eye implant in Europe, and FDA clearance for a new vaginitis test. These add future revenue streams and strengthen its pipeline and diagnostics franchise.

    These regulatory wins are new and support long-term growth, a core part of the investment case.

  • Nurix deal closes, but new eye competition emerges Roche closed its $2.3 billion Nurix collaboration for a blood cancer drug, gaining a promising asset. However, FDA approval of Outlook Therapeutics' Lytenava creates new competition for Roche's Avastin in eye disease, a modest negative.

    This shows both pipeline progress and a competitive threat, giving a balanced view.

▲3

Roche advances Alzheimer's, TB, lupus and AI, but Huntington's setback

  • Alzheimer's data and blood test progress Roche will present long-term trontinemab data and pTau217 blood test results at AAIC 2026, including a Phase III prevention study design. Positive data could boost confidence in its Alzheimer's pipeline and diagnostics, supporting future sales.

    This is new and shows pipeline progress that can drive future revenue.

  • UBS backs Roche as safer bet than AI UBS reiterated overweight on European pharma, preferring Roche among large caps due to improving earnings and low valuations. This can attract more investors, pushing the stock up.

    New analyst endorsement highlights a shift in capital flows toward Roche.

  • New TB test and lupus drug submission Roche received CE Mark for an automated TB test and has submitted obinutuzumab for lupus with FDA decision expected by December 2026. These expand diagnostics and treatment offerings, adding revenue potential.

    New product approvals and regulatory milestones support growth.

  • Nurix deal adds pipeline, but Huntington's failure Roche signed a $2.3 billion deal with Nurix for a promising blood cancer drug, but discontinued two Huntington's disease studies. The deal strengthens the pipeline, while the setback removes a potential therapy, balancing the impact.

    Both a positive pipeline boost and a negative clinical setback occurred this period.

Q2 2026
▲4

Roche's pipeline and diagnostics surge with FDA wins and new products

  • FDA accepts Lunsumio-Polivy combo filing FDA accepted Roche's filing for a chemotherapy-free lymphoma combo that cut progression risk by 59%. If approved, it opens a new treatment option in a hard-to-treat cancer, supporting future sales growth.

    New regulatory milestone that expands Roche's oncology portfolio and potential revenue.

  • FDA priority review for Enspryng in thyroid eye disease FDA granted priority review for Enspryng as a first at-home treatment for thyroid eye disease, with a decision due October 2026. This could add a new indication to an existing drug, boosting its sales potential.

    New regulatory catalyst that could broaden an approved drug's label and revenue.

  • Roche launches AXELIOS 1 gene sequencer, undercutting Illumina Roche launched its own next-generation sequencing platform at $750,000, below Illumina's machines. This challenges Illumina's 70% market share and opens a new growth avenue in the $7.3 billion sequencing market.

    New product launch that enters a large, fast-growing market and pressures a key competitor.

  • Divarasib beats approved KRAS inhibitors in Phase III Genentech's divarasib showed better progression-free and overall survival than current KRAS G12C drugs in lung cancer. Positive late-stage data raise the odds of a new blockbuster and strengthen Roche's pipeline.

    New clinical win that could lead to a best-in-class cancer drug and future revenue.

June 2026
▲4

Roche's pipeline and diagnostics surge with FDA wins and new products

  • FDA accepts Lunsumio-Polivy combo filing FDA accepted Roche's filing for a chemotherapy-free lymphoma combo that cut progression risk by 59%. If approved, it opens a new treatment option in a hard-to-treat cancer, supporting future sales growth.

    New regulatory milestone that expands Roche's oncology portfolio and potential revenue.

  • FDA priority review for Enspryng in thyroid eye disease FDA granted priority review for Enspryng as a first at-home treatment for thyroid eye disease, with a decision due October 2026. This could add a new indication to an existing drug, boosting its sales potential.

    New regulatory catalyst that could broaden an approved drug's label and revenue.

  • Roche launches AXELIOS 1 gene sequencer, undercutting Illumina Roche launched its own next-generation sequencing platform at $750,000, below Illumina's machines. This challenges Illumina's 70% market share and opens a new growth avenue in the $7.3 billion sequencing market.

    New product launch that enters a large, fast-growing market and pressures a key competitor.

  • Divarasib beats approved KRAS inhibitors in Phase III Genentech's divarasib showed better progression-free and overall survival than current KRAS G12C drugs in lung cancer. Positive late-stage data raise the odds of a new blockbuster and strengthen Roche's pipeline.

    New clinical win that could lead to a best-in-class cancer drug and future revenue.

▲4

Roche's pipeline and diagnostics surge with FDA wins and new products

  • FDA accepts Lunsumio-Polivy combo filing FDA accepted Roche's filing for a chemotherapy-free lymphoma combo that cut progression risk by 59%. If approved, it opens a new treatment option in a hard-to-treat cancer, supporting future sales growth.

    New regulatory milestone that expands Roche's oncology portfolio and potential revenue.

  • FDA priority review for Enspryng in thyroid eye disease FDA granted priority review for Enspryng as a first at-home treatment for thyroid eye disease, with a decision due October 2026. This could add a new indication to an existing drug, boosting its sales potential.

    New regulatory catalyst that could broaden an approved drug's label and revenue.

  • Roche launches AXELIOS 1 gene sequencer, undercutting Illumina Roche launched its own next-generation sequencing platform at $750,000, below Illumina's machines. This challenges Illumina's 70% market share and opens a new growth avenue in the $7.3 billion sequencing market.

    New product launch that enters a large, fast-growing market and pressures a key competitor.

  • Divarasib beats approved KRAS inhibitors in Phase III Genentech's divarasib showed better progression-free and overall survival than current KRAS G12C drugs in lung cancer. Positive late-stage data raise the odds of a new blockbuster and strengthen Roche's pipeline.

    New clinical win that could lead to a best-in-class cancer drug and future revenue.

© 2026 MarketDXWhy